Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ-M2010-5
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
01
Overview
TJ-M2010-5: sourced facts only. name: "We previously proved that TJ-M2010-5 is a novel MyD88 inhibitor." [PMID:41043521]; target: "We previously proved that TJ-M2010-5 is a novel MyD88 inhibitor." [PMID:41043521]; developer: "Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Wuhan 430030, China; Hubei Provincial Clinical Research Center for Child Growth, Development, and Metabolic Diseases, Wuhan 430030, China." [PMID:41043521]; stage: "This study revealed that TJ-M2010-5 significantly improved the body weight, blood glucose and lipid levels of HFD mice." [PMID:41043521]
02
Targets
MYD88 (Myeloid differentiation primary response protein MyD88)
Beyond the preview
Go deeper on TJ-M2010-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ-M2010-5.